Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARMNASDAQ:COEPNASDAQ:TPSTNASDAQ:TSBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARMCarisma Therapeutics$0.46+0.8%$0.24$0.14▼$1.90$20.27M1.633.74 million shs2.43 million shsCOEPCoeptis Therapeutics$8.39+0.3%$9.42$2.31▼$13.70$29.22M-0.59118,007 shs2,241 shsTPSTTempest Therapeutics$6.72+1.7%$6.98$5.35▼$39.00$24.74M-2174,875 shs76,264 shsTSBXTurnstone Biologics$0.35+4.6%$0.35$0.29▼$3.05$8.10M1.18255,921 shs13,115 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARMCarisma Therapeutics0.00%+132.90%+171.39%+9.03%-60.39%COEPCoeptis Therapeutics0.00%-6.59%-14.78%-1.65%+27.05%TPSTTempest Therapeutics0.00%-19.88%-3.50%-40.53%-82.47%TSBXTurnstone Biologics0.00%-4.99%+2.33%-12.94%-87.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARMCarisma Therapeutics3.3137 of 5 stars3.25.00.00.02.51.71.3COEPCoeptis Therapeutics1.3495 of 5 stars0.05.00.00.03.31.70.0TPSTTempest Therapeutics2.7754 of 5 stars3.35.00.00.03.40.00.6TSBXTurnstone Biologics3.297 of 5 stars2.85.00.00.03.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARMCarisma Therapeutics 2.43Hold$1.93323.08% UpsideCOEPCoeptis Therapeutics 2.00HoldN/AN/ATPSTTempest Therapeutics 2.50Moderate Buy$30.00346.43% UpsideTSBXTurnstone Biologics 1.50Reduce$0.4528.57% UpsideCurrent Analyst Ratings BreakdownLatest TSBX, TPST, COEP, and CARM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$16.00 ➝ $16.004/10/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.004/1/2025CARMCarisma TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $1.003/28/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$169.00 ➝ $91.003/28/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$611.00 ➝ $208.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARMCarisma Therapeutics$19.96M0.95N/AN/A$0.66 per share0.69COEPCoeptis Therapeutics$62.87K468.63N/AN/A$0.48 per share17.47TPSTTempest TherapeuticsN/AN/AN/AN/A$1.39 per shareN/ATSBXTurnstone Biologics$19.31M0.42N/AN/A$4.27 per share0.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARMCarisma Therapeutics-$86.88M-$1.56N/AN/AN/A-314.78%-957.20%-96.39%8/6/2025 (Estimated)COEPCoeptis Therapeutics-$21.27M-$5.80N/A∞N/AN/A-1,094.50%-219.97%N/ATPSTTempest Therapeutics-$29.49M-$17.98N/AN/AN/AN/A-187.44%-82.61%8/6/2025 (Estimated)TSBXTurnstone Biologics-$55.20M-$2.73N/AN/AN/AN/A-105.99%-87.27%8/13/2025 (Estimated)Latest TSBX, TPST, COEP, and CARM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025COEPCoeptis TherapeuticsN/A-$1.11N/A-$1.11N/AN/A5/13/2025Q1 2025CARMCarisma Therapeutics-$0.17-$0.22-$0.05-$0.22$2.47 million$3.65 million5/13/2025Q1 2025TPSTTempest Therapeutics-$3.71-$3.16+$0.55-$3.16N/AN/A5/8/2025Q1 2025TSBXTurnstone Biologics-$0.26-$0.51-$0.25-$0.51N/AN/A3/28/2025Q4 2024TSBXTurnstone Biologics-$0.69-$0.56+$0.13-$0.56N/AN/A3/27/2025Q4 2024TPSTTempest Therapeutics-$3.12-$4.03-$0.91-$0.31N/A$0.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARMCarisma TherapeuticsN/AN/AN/AN/AN/ACOEPCoeptis TherapeuticsN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARMCarisma Therapeutics1.393.233.23COEPCoeptis Therapeutics0.030.400.40TPSTTempest TherapeuticsN/A1.691.69TSBXTurnstone BiologicsN/A3.753.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARMCarisma Therapeutics44.27%COEPCoeptis Therapeutics13.88%TPSTTempest Therapeutics22.52%TSBXTurnstone Biologics52.51%Insider OwnershipCompanyInsider OwnershipCARMCarisma Therapeutics12.57%COEPCoeptis Therapeutics24.25%TPSTTempest Therapeutics4.70%TSBXTurnstone Biologics32.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARMCarisma Therapeutics2041.79 million36.50 millionNo DataCOEPCoeptis Therapeutics23.51 million2.46 millionNot OptionableTPSTTempest Therapeutics203.68 million41.59 millionOptionableTSBXTurnstone Biologics8223.14 million15.70 millionNot OptionableTSBX, TPST, COEP, and CARM HeadlinesRecent News About These CompaniesTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...May 8, 2025 | gurufocus.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsMay 8, 2025 | globenewswire.comTurnstone Biologics reports Q4 EPS (56c) vs (73c) last yearMarch 31, 2025 | markets.businessinsider.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | investing.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comTurnstone Biologics stock plunges to 52-week low of $0.4February 11, 2025 | msn.comTurnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?February 7, 2025 | zacks.comTurnstone Biologics to explore strategic alternativesFebruary 6, 2025 | thepharmaletter.comTurnstone ends last remaining clinical program due to costs, plots more layoffsFebruary 5, 2025 | fiercebiotech.comTurnstone Biologics halts TIDAL-01 development, seeks alternativesFebruary 5, 2025 | msn.comTurnstone Biologics downgraded to Neutral from Overweight at Piper SandlerFebruary 5, 2025 | markets.businessinsider.comTurnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True PotentialFebruary 5, 2025 | bovnews.comTurnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives ReviewFebruary 4, 2025 | quiverquant.comTurnstone Biologics Announces Plans to Explore Strategic AlternativesFebruary 4, 2025 | finance.yahoo.comBofA downgrades Turnstone to Underperform on unfavorable marketNovember 16, 2024 | markets.businessinsider.comTurnstone Biologics downgraded to Underperform from Neutral at BofANovember 16, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Turnstone Biologics Corp. (TSBX)November 15, 2024 | markets.businessinsider.comTurnstone Biologics Faces Financial and Operational ChallengesNovember 14, 2024 | markets.businessinsider.comTurnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsNovember 12, 2024 | markets.businessinsider.comWhat’s Behind the 18.75% Gain in Turnstone Biologics Corp (TSBX) Stock? Find Out Now!November 7, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSBX, TPST, COEP, and CARM Company DescriptionsCarisma Therapeutics NASDAQ:CARM$0.46 +0.00 (+0.75%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Coeptis Therapeutics NASDAQ:COEP$8.38 +0.03 (+0.30%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Tempest Therapeutics NASDAQ:TPST$6.72 +0.11 (+1.66%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.Turnstone Biologics NASDAQ:TSBX$0.35 +0.02 (+4.63%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
